# Advanced Medicine

Clinical and translational frontiers: immunotherapy, mRNA and gene editing, gene and cell therapy, incretin drugs, neurodegeneration, aging, infectious disease, cardiovascular therapeutics and clinical AI.

## Topics

- [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy) (288 papers): Immune checkpoint inhibitors, CAR-T and TIL cell therapies including solid tumors, T-cell engagers and bispecifics, and antibody-drug conjugates.
- [mRNA Therapeutics & Cancer Vaccines](https://space-kitty.com/topics/mrna-cancer-vaccines) (223 papers): Personalized neoantigen mRNA vaccines, lipid-nanoparticle delivery, self-amplifying and circular RNA and mRNA therapeutics beyond infectious disease.
- [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies) (264 papers): Approved and investigational CRISPR-Cas9 therapies, base and prime editing, in vivo LNP-delivered editing and bespoke editing for ultra-rare disease.
- [Gene & Cell Therapy](https://space-kitty.com/topics/gene-cell-therapy) (232 papers): AAV and lentiviral gene therapy, in vivo CAR-T, iPSC- and stem-cell-derived replacement therapies such as islets and dopaminergic neurons.
- [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic) (230 papers): Semaglutide, tirzepatide and next-generation incretin agonists; obesity, diabetes, cardiovascular, renal, liver and neuropsychiatric outcomes.
- [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration) (355 papers): Anti-amyloid antibodies, plasma p-tau biomarkers, alpha-synuclein seed amplification, antisense therapies for ALS and emerging disease-modifying strategies.
- [Biology of Aging & Longevity](https://space-kitty.com/topics/aging-longevity) (306 papers): Hallmarks of aging, senolytics, epigenetic clocks, partial reprogramming, mTOR and other geroprotective interventions.
- [Infectious Disease, Vaccines & Antimicrobial Resistance](https://space-kitty.com/topics/infectious-disease-amr) (253 papers): New antibiotic classes and AI-discovered antibiotics, phage therapy, long-acting HIV prevention and next-generation vaccines.
- [AI in Clinical Medicine](https://space-kitty.com/topics/ai-medicine) (279 papers): Validated diagnostic AI, medical large language models, AI-discovered drug candidates in clinical trials and evidence standards for clinical deployment.
- [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation) (252 papers): Lipoprotein(a)-lowering drugs, siRNA and gene-editing approaches to LDL cholesterol, CETP inhibition and other cardiovascular advances.

## Dossiers

- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic) ($0.20): Covers semaglutide, tirzepatide, the new oral GLP-1 agonists and next-generation triple-agonist and amylin-combination drugs, with their effects on weight, diabetes, cardiovascular, kidney, heart-failure, liver, sleep-apnea, joint and brain outcomes as of October 2026. The central takeaway: the field has moved from proving weight loss to proving organ protection. Placebo-adjusted mean weight loss at the top doses of pivotal trials in adults without diabetes now ranges from about 9 percentage points (oral orforglipron) to about 21 (retatrutide, not yet approved), and the main open questions are durability after stopping, lean-mass and rare safety signals, cost and access, and how much of the benefit is independent of weight loss.
---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.